TP53mutation status and gene expression profiles are powerful prognostic markers of breast cancer

Breast Cancer Research

Table 2 Cox regression analysis for breast cancer death for all patients (n = 179 to 200)

	Univariate analysis			Multivariate analysis
	RR	95 percent CI	P	RR	95 percent CI	P
Age, ≥55 years versus <55 years	0.86	0.51–1.44	0.57
Tumor type (overall effect)			0.14
Lobular (versus ductal)	0.56	0.30–1.06	0.074
Other (versus ductal)	0.66	0.26–1.67	0.38
Tumor size (overall effect)			0.001			0.002
pT2 (versus pT1)	2.22	1.17–4.20	0.014	1.94	0.99–3.82	0.054
pT3–pT4 (versus pT1)	4.17	1.93–9.01	0.0003	4.44	1.95–10.1	0.0004
Lymph node status (overall effect)			0.035			0.027
pN1 (versus pN0)	1.34	0.69–2.62	0.39	1.09	0.54–2.21	0.81
pN2–pN3 (versus pN0)	3.42	1.82–6.41	0.0001	2.73	1.41–5.30	0.003
Other^a (versus pN0)	1.69	0.77–3.67	0.19	1.28	0.51–3.20	0.60
Histological grade (overall effect)			0.47
G2 (versus G1)	0.99	0.39–2.50	0.98
G3 (versus G1)	1.43	0.52–3.90	0.49
TP53 mutation (versus wild type)	4.51	2.69–7.56	<0.0001	5.24	3.03–9.07	<0.0001
ER positive (versus negative)	0.72	0.43–1.22	0.23
PR positive (versus negative)	0.82	0.49–1.36	0.44

^aLymph nodes not removed. 95 percent CI, 95 percent confidence interval for relative risk; ER, estrogen receptor; PR, progesterone receptor;P, P value for the hypothesis of no effect; RR, relative risk (hazard ratio).

ISSN: 1465-542X